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Scavenger receptor class B, type I (SR-BI) is the main receptor for high-density lipoprotein (HDL) and an
emerging atheroprotective candidate. A central function of SR-BI is the delivery of HDL-derived
cholesterol to the liver for subsequent excretion into the bile. Here, we investigated the regulation of
SR-BI by the unfolded protein response (UPR), an adaptive mechanism induced by endoplasmic reticu-
lum (ER) stress, which is frequently activated in metabolic disorders.
We provide evidence that induction of acute ER stress by well-characterized chemical inducers leads
to decreased SR-BI expression in hepatocyte-derived cell lines. This results in a functional reduction of
selective lipid uptake from HDL. However, the regulation of SR-BI by ER stress is not a direct consequence
of altered cellular cholesterol metabolism. Finally, we show that SR-BI down-regulation by the UPR might
be a compensatory mechanism to provide partial adaption to ER stress.
The observed down-regulation of SR-BI by ER stress in hepatic cells might contribute to the unfa-
vorable effects of metabolic disorders on cholesterol homeostasis and cardiovascular diseases.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
High-density lipoprotein (HDL) is a transport vehicle for lipids in
the bloodstream. Speciﬁcally, it transports cholesterol from pe-
ripheral tissues to the liver for disposal into the bile. This process is
termed reverse cholesterol transport (RCT). In the ﬁrst step of RCT,
HDL removes excess cholesterol from macrophage foam cells,
which are directly involved in atherosclerotic plaque formation.
Finally, HDL transfers its cholesterol cargo to hepatocytes for sub-
sequent excretion into the bile [1,2].
Scavenger receptor class B, type I (SR-BI) plays a crucial role in
RCT, since it mediates the transfer of cholesteryl esters from HDL to6; CHOP, C/EBP-homologous
containing protein 4; GRP78,
y lipoprotein; IRE1, inositol-
doplasmic reticulum kinase;
ceptor class B, type I; SREBP,
ded protein response.
(C. R€ohrl).
inical Medicine, University of
r Inc. This is an open access articlehepatocytes, which is termed selective lipid uptake [3]. In mice,
hepatic SR-BI over-expression increases clearance of plasma
cholesterol. In contrast, loss of hepatic SR-BI results in elevated
plasma cholesterol levels triggering atherosclerosis [4,5]. More
recently, low abundance mutations in SR-BI were found to raise
HDL plasma cholesterol in humans, indicating impaired clearance
into the liver [6,7]. These ﬁndings establish an important role for
SR-BI in human and rodent cholesterol metabolism.
Metabolic disorders, in particular insulin resistance, obesity and
fatty liver disease are associated with hepatic endoplasmic reticu-
lum (ER) stress [8]. This disturbance of ER homeostasis leads to an
adaptive response, referred to as the unfolded protein response
(UPR). The UPR is initiated by three ER-resident proteins (ATF6,
PERK and IRE1) that are activated by ER stress. The UPR enables
adaptive mechanisms counteracting ER stress. On the other hand,
excess UPR-activity triggers apoptosis in cases ER homeostasis
cannot be restored [9].
Activation of ATF6 requires cleavage by the very same proteases
that process sterol regulatory element binding proteins (SREBPs),
central transcription factors in the regulation of cellular cholesterol
homeostasis [10]. This observation was the ﬁrst to connect the UPR
with lipid metabolism. Since then, a number of research groups
have investigated the cross-talk between ER stress and cholesterolunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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UPR has not been investigated yet, although SR-BI is a crucial
regulator of cholesterol metabolism. We have therefore investi-
gated the effect of the induction of ER stress on the expression of
SR-BI and its functional consequences in hepatocyte-derived cell
lines.
2. Material and methods
2.1. Cell culture
HepG2 cells (ATCC: HB-8065) were cultivated in MEM supple-
mented with 10% FBS, 1% penicillin/streptomycin and 1% non-
essential amino acids (all from Sigma-Aldrich, St. Louis, US). Huh-
7 (ATCC: JCRB-0403) cells were cultivated in DMEM containing
10% FBS and 1% penicillin/streptomycin. All incubations were per-
formed in media containing 10% FBS, unless otherwise indicated.
Thapsigargin, tunicamycin, lovastatin and mevalonate were ob-
tained from Sigma-Aldrich. DMSO was used as a solvent for thap-
sigargin and tunicamycin. Final concentrations of DMSO were kept
<0.1% and did not inﬂuence ER stress (data not shown).
Lipoprotein-deﬁcient serum (lpds) was prepared from FBS as
described [12]. For cholesterol depletion, cells were incubated with
MEM containing 10% lpds, 5 mM lovastatin and 100 mMmevalonate
[13].
2.2. qRT-PCR, immunoblotting
qRT-PCR and immunoblotting were performed according to
standard methods. TaqMan IDs and details on antibodies are given
in Tables S1 and S2 (see supplemental methods).
2.3. siRNA knock-down
Reagents for siRNA knockdownwere obtained from Dharmacon
(GE Healthcare, Chalfont St. Giles, GB). Cells were transfected with
DharmaFECT and 25 nM ON-TARGETplus SMARTpool siRNA against
ATF6 (L-009917), PERK (L-004883), IRE1 (L-041030) or non-
targeting siRNA (D-001810) for 48 h followed by induction of ER
stress.
2.4. Selective lipid uptake
HDL was isolated from healthy normolipidemic volunteers by
sequential ﬂotation ultracentrifugation [14]. Isolation of HDL from
human subjects was approved by the ethics committee of the
Medical University of Vienna (#1414/2016). Selective lipid uptake
was assessed using HDL double-labeled in its apolipoprotein (125I)
and lipid moiety (3H-cholesteryl oleate) as described previously
[15].
2.5. shRNA-mediated knock-down of SR-BI
Lentiviral shRNA-mediated knock-down of SR-BI in HepG2 cells
was performed as described previously. SR-BI knockdown cells
display a 90% reduction in SR-BI protein expression and a 75%
reduction of selective cholesteryl-ester uptake compared to
scrambled shRNA control cells [15].
2.6. Statistics
Data are depicted as mean ± SD. 2-sided t-tests were applied to
compare two experimental groups. ANOVA followed by Tukey's
multiple testing corrections was used to compare more than two
groups. Signiﬁcant p-values are indicated as * (<0.05), ** (<0.01) or*** (<0.001).
3. Results
HepG2 cells retain key features of hepatocyte cholesterol
metabolism such as secretion of apolipoproteins and lipoprotein
particle formation and are therefore widely used as a model system
for hepatocytes in lipid research [16]. Thapsigargin and tunicamy-
cin, which interfere with cellular calcium homeostasis and glyco-
sylation, respectively, were used as established pharmacological
inducers of ER stress [17,18]. Fig. 1a shows an overview of the three
branches of the UPR and selected down-stream targets which were
used to monitor UPR activity. As expected, both thapsigargin and
tunicamycin induced all branches of the UPR in HepG2 cells as
monitored by increased expression of the UPR down-stream targets
GRP78 (ofﬁcial gene name: HSPA5; also known as BiP), CHOP
(ofﬁcial gene name: DDIT3) and ERdJ4 (ofﬁcial gene name: DNAJB9)
(Fig. 1b). Concomitantly, both substances decreased SR-BI protein
expression to ~50% (Fig. 1c). SR-BI mRNAwas likewise reduced in a
dose-dependent manner (Fig. 1d). Changes in SR-BI mRNA levels
lagged behind induction of GRP78 mRNA (Fig. 1e). After 8 h, GRP78
expression was fully activated whereas alterations in SR-BI mRNA
became apparent afterwards. These data indicate that SR-BI is not
an immediate UPR response gene. Huh-7 cells, another human
hepatocyte-derived cell line, responded to tunicamycin and thap-
sigargin comparably to HepG2 cells in terms of a reduction of SR-BI
expression (Fig. 1f). Similarly, induction of ER stress in immortal-
ized human hepatocytes (IHH) and Hepa1-6murine hepatoma cells
reduced SR-BI expression (Fig. S1). Taken together, induction of ER
stress reduces SR-BI expression in human and murine hepatic cells.
We and others have previously shown that ER stress severely
interferes with cellular cholesterol homeostasis and SREBP-2 ac-
tivity [19e21]. We therefore investigated, if the regulation of SR-BI
via the UPR depends on cellular cholesterol levels by depleting cells
from cholesterol. As expected, this resulted in compensatory acti-
vation of SREBP-2 as monitored by increased LDL-receptor
expression (Fig. 2a). Interestingly, LDL-receptor expression was
modulated differentially by thapsigargin and tunicamycin. How-
ever, the response of SR-BI to ER stress induction remains the same
under cholesterol depletion (Fig. 2a, b), indicating that the down-
regulation of SR-BI by the UPR is not tightly linked to alterations
in cellular cholesterol content or activation of SREBP-2. Next, we
investigated, which of the three UPR-branches mediates SR-BI
down-regulation by selective siRNA knockdown of ATF6, PERK or
IRE1. However, thapsigargin was still effective in suppressing SR-BI
expression when single ER stress branches were depleted (Fig. 2c,
d). In contrast, knockdown of ATF6 rescued thapsigargin-mediated
down-regulation of ABCA1, which we have observed previously
[19]. This indicates that the regulatory mechanisms controlling SR-
BI expression under ER stress are more complex and possibly
require the interconnection of two or all three ER stress branches.
A major function of SR-BI is binding of HDL and transfer of
cholesteryl esters into cells, a process termed selective lipid uptake.
Thus, alterations in selective lipid uptake after thapsigargin and
tunicamycin treatment were analyzed (Fig. 3). Thapsigargin
reduced cell association of HDL protein as well as cholesteryl esters
(Fig. 3a). The response to tunicamycin was similar, although the
effects were less prominent (Fig. 3b). Noteworthy, cell association
of cholesteryl esters exceeded association of HDL protein, indicative
of selective cholesteryl ester transfer to cells. In summary, induc-
tion of ER stress reduces SR-BI expressionwhich is accompanied by
functionally relevant reduced selective lipid uptake from HDL.
We then speculated that the reduction of SR-BI in response to ER
stress might be an adaptive mechanism helping to ameliorate ER
stress. Thus, we induced ER stress in HepG2 cells after shRNA-
Fig. 1. Endoplasmic reticulum (ER) stress is a negative regulator of SR-BI. A) An overview of the unfolded protein response (UPR). Selected UPR-down-stream targets of the three
individual UPR-branches (ATF6, PERK and IRE1) are indicated, which were used to assess the activity of the UPR in our study. B) HepG2 cells were treated with 0.1 mM thapsigargin
or 1 mM tunicamycin for 24 h. UPR-activity was assessed by qRT-PCR (n ¼ 4e5). C) HepG2 cells were treated with 1 mM thapsigargin or 10 mM tunicamycin for 24 h. SR-BI expression
was assessed by immunoblotting and quantiﬁed by densitometry (n ¼ 4). D) HepG2 cells were treated with the indicated concentrations of thapsigargin for 24 h and gene
expression was examined by qRT-PCR (n ¼ 2). E) HepG2 cells were treated with 0.1 mM thapsigargin for the indicated times and gene expression was assessed by qRT-PCR (n ¼ 2). F)
SR-BI expression was analyzed in Huh-7 cells as described for C); n ¼ 4.
Fig. 2. Regulation of SR-BI is not a direct consequence of altered cholesterol metabolism. A) and B) HepG2 cells were treated with 1 mM thapsigargin or 5 mM tunicamycin in media
containing 10% FBS or in cholesterol depletion media (see Material and Methods) for 24 h. Protein expression was assessed by immunoblotting and SR-BI expression was quantiﬁed
by densitometry (n ¼ 3). C) and D) Individual ER stress branches were targeted by siRNA and cells were incubated with 0.1 mM thapsigargin for 24 h. Protein expressionwas assessed
by immunoblotting and SR-BI expression was quantiﬁed by densitometry (n ¼ 3).
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Fig. 3. ER stress reduces selective lipid uptake. HepG2 cells were treated with the
indicated concentrations of thapsigargin (A) or tunicamycin (B) for 24 h. Speciﬁc cell
association of HDL labeled in its apolipoprotein (125I) and lipid moiety (3H-cholesteryl
oleate) was assessed for 1 h in serum-free media containing 2 mg/ml fatty-acid free
BSA. Values were normalized to cell protein (n ¼ 6).
Fig. 4. Down-regulation of SR-BI provides partial amelioration of ER stress. HepG2 cell clo
were treated with 1 mM thapsigargin or 10 mM tunicamycin for 24 h and gene expression o
T. Eberhart et al. / Biochemical and Biophysical Research Communications 479 (2016) 557e562560mediated knock-down of SR-BI (Fig. 4a). Activation of all three UPR-
branches was lower in HepG2 cells lacking SR-BI after thapsigargin
treatment. Of note, these effects were not observed when ER stress
was induced by tunicamycin (Fig. 4bed). Down-regulation of SR-BI
by the UPR therefore provides partial protection from ER stress.4. Discussion
Metabolic disorders like obesity and insulin resistance cause
hepatic ER stress [22]. Furthermore, these disorders are risk factors
for atherosclerosis. We have therefore investigated the regulation
of SR-BI, a signiﬁcant player in cholesterol metabolism, by ER stress
in hepatic cells. Our results provide evidence that the induction of
ER stress down-regulates SR-BI expression in a panel of hepatocyte-
derived cell lines resulting in functional down-regulation of se-
lective lipid uptake from HDL. We have previously shown that ER
stress also impairs expression of ABCA1 and causes a reduction of
cholesterol efﬂux to apoA-I, which is a central step in the formation
of nascent HDL [19]. Thus, induction of the UPR leads to a reduction
of HDL formation as well as a reduction of clearance of HDL-derived
cholesterol. We anticipated that this concomitant regulation is
detrimental for reverse cholesterol transport (RCT), the ﬂux of
cholesterol from peripheral tissues - such as atherosclerotic lesions
- to the liver for disposal into the bile. Hepatic ER stress might
therefore negatively impact atherosclerosis and cardiovascular
diseases. It would be highly interesting to assess RCT in animal
models of hepatic ER stress, where we expect decreased RCT.
A central role in the regulation of cholesterol homeostasis is
attributed to SREBP-2, which is regulated by cellular cholesterol
levels and in turn is a regulator of cholesterol uptake and synthesis.
ER stress has been reported to deregulate SREBP-2 activity inde-
pendently of cellular cholesterol [20,21]. In line, the regulation of
SR-BI by ER stress seems to be independent of cellular cholesterolnes stably expressing shRNA against SR-BI or scrambled control were generated. Cells
f SR-BI and UPR-down-stream targets were determined by qRT-PCR (n ¼ 4).
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UPR overrules central regulatory mechanisms in cholesterol ho-
meostasis making cells incapable to sense and regulate cholesterol
homeostasis.
Both thapsigargin and tunicamycin activate each of the three ER
stress branches making them valuable compounds to investigate
consequences of UPR induction. In-vivo, each of the three UPR
branches was reported to affect hepatic lipid metabolism [23e25].
However, the UPR branches are not necessarily uniformly activated
in-vivo and are characterized by a complex interconnection. For
instance, ATF6 was reported to be down-regulated in obesity by the
hepatic co-repressor DACH1, which in turn triggers PERK activation
[26]. Therefore, induction of ER stress using thapsigargin and
tunicamycin, which activate all UPR branches, does not necessarily
tightly reﬂect complex in-vivo situations. This may be a limitation
of our study. This could also be the reason, why knockdown of
single UPR branches failed to identify themechanisms that regulate
SR-BI expression after induction of ER stress (see Fig. 2c, d).
Our data further indicate that SR-BI deﬁciency provides partial
protection from ER stress. Thus the down-regulation of SR-BI by the
UPR has to be considered an adaptive mechanism to mitigate ER
stress. Although the role of SR-BI in the regulation of ER stress has
not been investigated before, a protective role has been attributed
to HDL: HDL inhibits ER stress that is induced by oxidized LDL in
endothelial cells [27]. In addition, HDL protects pancreatic b-cells
from ER stress induced by thapsigargin, palmitate or insulin over-
expression. However, the authors of this study report that HDL's
protective function is independent from SR-BI [28]. Hence, other
HDL receptors present on hepatic cells such as Ecto-F1-ATPase [29]
possibly mediate HDL's protective effects. Altogether, this suggests
that the protection from ER stress provided by SR-BI reduction is
independent from its role of being an HDL receptor. However, SR-BI,
besides being a cell surface cholesterol transporter, has additional
functions in intracellular cholesterol trafﬁcking [30]. In obesity,
hepatic ER stress leads to modiﬁcations in ER lipid composition
which interfere with ER calcium homeostasis via the calcium pump
SERCA [31]. Thus, the down-regulation of SR-BI by the UPR might
lead to SR-BI-mediated alterations in ER lipid composition, which
might alter SERCA activity to ameliorate ER stress caused by aber-
rant calcium metabolism. This could explain, why SR-BI deﬁciency
protects from thapsigargin, but not from tunicamycin induced ER
stress (compare Fig. 4), as thapsigargin, but not tunicamycin, in-
terferes with ER calcium homeostasis.
Taken together we suggest that the observed down-regulation
of SR-BI by ER stress might contribute to the unfavorable effects
of metabolic disorders on cholesterol homeostasis and cardiovas-
cular diseases. Targeting ER stress in patients with metabolic syn-
drome by chemical chaperones such as 4-PBA or TUDCA [32] might
be a potential therapeutic approach to ameliorate dyslipidemia in
these patients.
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